Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of... see more

Recent & Breaking News (NDAQ:MRNS)

Today's Research Report Coverage on Biotech Stocks -- Marinus Pharma, NewLink Genetics, Akcea Therapeutics, and Amgen

PR Newswire October 2, 2017

20 Biggest Mid-Day Gainers For Monday

Benzinga.com  September 25, 2017

Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 21, 2017

Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter’s option to purchase additional shares

GlobeNewswire September 19, 2017

18 Biggest Mid-Day Gainers For Friday

Benzinga.com  September 15, 2017

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

GlobeNewswire September 15, 2017

5 Stocks To Watch For September 15, 2017

Benzinga.com  September 15, 2017

Marinus Pharmaceuticals Announces Public Offering of Common Stock

GlobeNewswire September 14, 2017

Mid-Day Market Update: Dow Up 1%; Achillion Pharmaceuticals Shares Plunge

Benzinga.com  September 11, 2017

Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone

GlobeNewswire September 11, 2017

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results

GlobeNewswire August 1, 2017

FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder

GlobeNewswire June 29, 2017

Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression

GlobeNewswire June 27, 2017

How These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma

PR Newswire May 18, 2017

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results

GlobeNewswire May 1, 2017

Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer

GlobeNewswire April 11, 2017

Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference

GlobeNewswire April 10, 2017

Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone

Business Wire April 5, 2017

Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference

GlobeNewswire March 15, 2017

Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results

GlobeNewswire March 13, 2017